Elite Pharmaceuticals, with a market capitalization of $531 million, reported a decline in third-quarter revenue for 2024, falling 8% from the previous year. Despite a strong nine-month performance, ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...

For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

WEST LAFAYETTE − Purdue basketball's defense got it through a tough road trip to the Pacific Northwest. The Boilermakers saw their seven-game winning streak end because the offense couldn't ...

Alliance Pharma said that expected revenue fell, dragged down by consumer healthcare, and stuck to its guidance for the year. The medicine and healthcare-product supplier said Friday that expected ...

Gross Margin: Increased 5% across all operating segments. Pharmaceutical and Specialty Solutions Revenue: Decreased 4% to $51 billion; excluding customer transition, increased 17%. Pharmaceutical ...

The Purdue and Indiana men's basketball teams faced ... or illegally or any sort of professional advice. Gannett may earn revenue from sports betting operators for audience referrals to betting ...

Despite the dangers, insurance companies, pharmacy managers and drugmakers like Purdue Pharma for years pushed for the use of opioids in pursuit of immense profits. The resulting overdose crisis has ...